These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 1986564

  • 1. The effect of angiotensin-converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria.
    Don BR, Kaysen GA, Hutchison FN, Schambelan M.
    Am J Kidney Dis; 1991 Jan; 17(1):10-7. PubMed ID: 1986564
    [Abstract] [Full Text] [Related]

  • 2. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 3. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW.
    Am J Kidney Dis; 2000 Mar; 35(3):427-32. PubMed ID: 10692268
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial.
    Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ.
    Am J Kidney Dis; 1996 Apr; 27(4):489-95. PubMed ID: 8678058
    [Abstract] [Full Text] [Related]

  • 5. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M, Tylicki L, Rutkowski P, Rutkowski B.
    Scand J Urol Nephrol; 2004 Apr; 38(5):427-33. PubMed ID: 15764256
    [Abstract] [Full Text] [Related]

  • 6. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M.
    Ann Intern Med; 1993 Apr 15; 118(8):577-81. PubMed ID: 8452322
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome.
    Garini G, Mazzi A, Allegri L, Buzio C, Borghetti A.
    Miner Electrolyte Metab; 1996 Apr 15; 22(1-3):123-7. PubMed ID: 8676802
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
    Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H.
    BMC Nephrol; 2002 Feb 14; 3():2. PubMed ID: 11869456
    [Abstract] [Full Text] [Related]

  • 9. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L, Rutkowski P, Renke M, Rutkowski B.
    Am J Nephrol; 2002 Feb 14; 22(4):356-62. PubMed ID: 12169868
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
    Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G.
    Kidney Blood Press Res; 1998 Feb 14; 21(1):66-9. PubMed ID: 9661139
    [Abstract] [Full Text] [Related]

  • 11. The influence of angiotensin-converting enzyme inhibition on renal tubular function in progressive chronic nephropathy.
    Kamper AL, Holstein-Rathlou NH, Leyssac PP, Strandgaard S.
    Am J Kidney Dis; 1996 Dec 14; 28(6):822-31. PubMed ID: 8957033
    [Abstract] [Full Text] [Related]

  • 12. Effects of short-term glycemic control, low protein diet and administration of enalapril on renal hemodynamics and protein permselectivity in type 2 diabetic patients with microalbuminuria.
    Narita T, Koshimura J, Suzuki K, Murata M, Meguro H, Fujita H, Kitazato H, Ito S.
    Tohoku J Exp Med; 1999 Oct 14; 189(2):117-33. PubMed ID: 10775055
    [Abstract] [Full Text] [Related]

  • 13. Modulation of albuminuria by dietary protein and converting enzyme inhibition.
    Hutchinson FN, Schambelan M, Kaysen GA.
    Am J Physiol; 1987 Oct 14; 253(4 Pt 2):F719-25. PubMed ID: 2821830
    [Abstract] [Full Text] [Related]

  • 14. In vivo visualization of the antialbuminuric effects of the angiotensin-converting enzyme inhibitor enalapril.
    Schießl IM, Kattler V, Castrop H.
    J Pharmacol Exp Ther; 2015 May 14; 353(2):299-306. PubMed ID: 25680709
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients.
    Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F.
    Hypertension; 1992 Feb 14; 19(2 Suppl):II237-42. PubMed ID: 1735586
    [Abstract] [Full Text] [Related]

  • 16. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul 14; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS.
    Kidney Int; 2000 Feb 14; 57(2):590-600. PubMed ID: 10652036
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.
    Keyzer CA, de Jong MA, Fenna van Breda G, Vervloet MG, Laverman GD, Hemmelder M, Janssen WM, Lambers Heerspink HJ, Navis G, de Borst MH, Holland Nephrology Study (HONEST) Network.
    Nephrol Dial Transplant; 2016 Jul 14; 31(7):1081-7. PubMed ID: 25744274
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 20. Differing actions of dietary protein and enalapril on renal function and proteinuria.
    Hutchison FN, Martin VI, Jones H, Kaysen GA.
    Am J Physiol; 1990 Jan 04; 258(1 Pt 2):F126-32. PubMed ID: 2301589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.